SecBot SecBot
Biotech Drug Report Generated Aug 24, 2026

efimosfermin

GSK·GSK plc
NEUTRAL
Drug Impact Rating3/10
Trial phase
Phase 2
Time to market
Uncertain. Phase 2 is complete; GSK will need to design and execute Phase 3 trials before any regulatory filing, which typically takes 3-5+ years for a novel MASH therapy.
Why 3/10
No hard, dated catalyst (PDUFA, pivotal readout, or regulatory decision) is scheduled for efimosfermin within the next ~12 months. The Phase 2 trial (NCT04880031) is complete, and while Breakthrough/PRIME designations are positive signals, there is no registered Phase 3 trial or known regulatory submission date. Additionally, efimosfermin is a tiny pipeline asset inside a ~$106B mega-cap pharma, limiting any single-drug impact on GSK shares.
⚠ Few sources Few sources were found for this drug. Treat the rating as low-confidence and verify against the cited sources.
Actionable Insight NEUTRAL

Monitor for GSK-initiated Phase 3 trial registration and for formal Phase 2 data disclosure at a hepatology conference (e.g., AASLD/EASL). Neither event has a confirmed date, so efimosfermin is not a near-term trading catalyst for GSK. The drug is a small pipeline component of a diversified pharma giant and carries limited stock-moving potential even on positive news.

Price Chart

Loading chart...

Executive Summary

Efimosfermin (development code BOS-580) is GSK's investigational therapy for MASH (formerly NASH), a progressive liver disease with limited treatment options. A 231-patient Phase 2 trial completed in October 2025, and the data earned FDA Breakthrough Therapy and EMA PRIME designations in early 2026 based on improvements in liver fibrosis and MASH resolution. However, Phase 2 results have not been formally published, no Phase 3 trial has been registered, and the drug represents a negligible portion of GSK's ~$106B market cap. This is a promising but very early-stage pipeline asset in a historically difficult therapeutic area, positive de-risking, but not a stock-moving catalyst anytime soon.

How It Works

Efimosfermin (BOS-580) is an investigational injectable therapy for MASH (metabolic dysfunction-associated steatohepatitis, formerly called NASH), a serious liver disease caused by fat buildup that leads to inflammation and scarring. It works by targeting metabolic pathways involved in liver fibrosis (scarring) and inflammation. Exactly which biological pathway it modulates (likely an FGF21-analog mechanism based on the drug class and indication) has not been disclosed publicly by GSK in available filings.

Trial Status

A 231-patient Phase 2 trial (NCT04880031) in obese subjects at risk for, or with biopsy-confirmed, NASH completed primary data collection in October 2025. Trial results have not been publicly posted yet (hasResults=false on ClinicalTrials.gov), but the data was sufficiently positive to earn FDA Breakthrough Therapy designation and EMA PRIME designation in early 2026 for the treatment of MASH. These designations are based on Phase II data showing improvement in liver fibrosis and MASH resolution.

The Two-Sided Case

▲ Bull Case3
FDA Breakthrough Therapy and EMA PRIME designations signal strong Phase 2 efficacy and a clear regulatory path, these designations provide expedited review and more frequent FDA interaction, potentially accelerating development timelines.
MASH represents a massive unmet medical need with no approved therapies specifically indicated for advanced liver fibrosis due to MASH. Madrigal Pharmaceuticals' Rezdiffra (resmetirom) is the only FDA-approved MASH drug (for F2/F3 fibrosis), leaving enormous room for additional therapies.
GSK has deep pockets and a strong track record of advancing drugs through late-stage development, reducing the risk of financial constraints that often kill promising mid-stage assets at smaller biotechs.
▼ Bear Case4
Efimosfermin is a tiny, early-stage asset within GSK's massive pipeline. GSK has a market capitalization of ~$106B, so even a successful MASH approval would have a modest effect on GSK's stock price on a percentage basis.
The MASH/NASH competitive landscape is crowded and littered with late-stage failures. Multiple large pharma drugs have failed Phase 2/3 trials, and Rezdiffra (Madrigal) already has first-mover advantage as the only approved therapy.
Phase 2 results have not been formally published or presented at a medical congress (hasResults=false on ClinicalTrials.gov as of the latest update), so investors cannot independently verify the efficacy signal that earned the breakthrough designations.
No Phase 3 trial has been registered or initiated yet, meaning significant additional capital expenditure and timeline risk remains before any potential approval.

Upcoming Catalysts

  • Full Phase 2 data disclosure at a medical conference (date not announced)
  • Initiation of Phase 3 trial design/start
  • Any regulatory meeting outcomes regarding Phase 3 pathway

Source Filing

The SecBot filing or press-release report that triggered this drug report:

GSK plc 6-K GSK ·Originating report

Sources · 1

Hover a chip for the title
1 sec.gov